NSCLC, Recurrent

12 registered clinical trials studyying NSCLC, Recurrent — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	A Study to Evaluate the Safety and Efficacy of Mesothelin-Targeting Logic-gated CAR T, in Participants With So NCT06051695	A2 Biotherapeutics Inc.	Phase 1 / Phase 2
Terminated	A Biomarker Screening Protocol for Participants With Solid Tumors NCT05891197	Lyell Immunopharma, Inc.	—
Active Not Recruiting	A Study to Evaluate the Safety and Efficacy of A2B530, a Logic-gated CAR T, in Participants With Solid Tumors NCT05736731	A2 Biotherapeutics Inc.	Phase 1 / Phase 2
Recruiting	Combination of Atezolizumab and Pirfenidone in Second-line and Beyond NSCLC NCT04467723	University of Kansas Medical Center	Phase 1 / Phase 2
Terminated	A Study to Investigate LYL797 in Adults With Solid Tumors NCT05274451	Lyell Immunopharma, Inc.	Phase 1
Unknown	Dacomitinib Treatment Followed by 3rd Generation EGFR-TKI in Patients With EGFR Mutation Positive Advanced NSC NCT04768491	Peking Union Medical College	—
Unknown	Prospective Observation of Failure Patterns in NSCLC Treated With ICIs NCT04492969	Fudan University	—
Unknown	Microbiome in Immunotherapy naïve NSCLC Patients Receiving PD-1/L1 Blockade (MIP_NSCLC) NCT04636775	Jun Zhang, MD, PhD	—
Withdrawn	Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma NCT03361319	Royal Marsden NHS Foundation Trust	Phase 1 / Phase 2
Terminated	Study of Tarloxotinib in Pts With NSCLC (EGFR Exon 20 Insertion, HER2-activating Mutations) & Other Solid Tumo NCT03805841	Rain Oncology Inc	Phase 2
Recruiting	Molecular Landscape Analysis and Clinical Implications for NSCLC Patients With Rare Mutations NCT05701787	Shanghai Chest Hospital	—
Terminated	Carboplatin Plus Pemetrexed Plus Atezolizumab Plus Bevacizumab in Chemotherapy and Immunotherapy-naïve Patient NCT03713944	Nasser Hanna	Phase 2